Xenon Pharmaceuticals Inc XENE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XENE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $40.41
- Day Range
- $39.77–40.61
- 52-Week Range
- $28.00–50.69
- Bid/Ask
- $40.55 / $40.67
- Market Cap
- $3.06 Bil
- Volume/Avg
- 305,722 / 349,295
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 259
- Website
- https://www.xenon-pharma.com
Comparables
Valuation
Metric
|
XENE
|
PLRX
|
EWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.44 | 1.95 | 3.08 |
Price/Sales | — | 3,406.41 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
XENE
PLRX
EWTX
Financial Strength
Metric
|
XENE
|
PLRX
|
EWTX
|
---|---|---|---|
Quick Ratio | 31.52 | 15.95 | 36.49 |
Current Ratio | 31.82 | 16.12 | 37.08 |
Interest Coverage | — | −138.69 | — |
Quick Ratio
XENE
PLRX
EWTX
Profitability
Metric
|
XENE
|
PLRX
|
EWTX
|
---|---|---|---|
Return on Assets (Normalized) | −19.59% | −23.39% | −23.18% |
Return on Equity (Normalized) | −20.49% | −25.61% | −24.45% |
Return on Invested Capital (Normalized) | −24.56% | −29.08% | −28.92% |
Return on Assets
XENE
PLRX
EWTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dyscxwfcp | Gtcf | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yzsjsvbcx | Rcjgmzr | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vkkncgdxf | Zbxynqd | $107.8 Bil | |
MRNA
| Moderna Inc | Lxdmcyyv | Ymxh | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Tcfbxjc | Ppqvd | $22.2 Bil | |
ARGX
| argenx SE ADR | Cyjzlln | Nqpt | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nbgjknhrb | Gwjvbvc | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nzvlyyc | Nglgmp | $15.1 Bil | |
INCY
| Incyte Corp | Pkljgny | Rxygkd | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wwfgmjvzws | Cvglyg | $12.7 Bil |